Aldeyra Therapeutics (ALDX) Current Leases (2019 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Current Leases came in at $212769.0 in Q1 2026, down 16.67% YoY from $255342.0 in Q1 2025, and down 24.16% on a QoQ basis from $280537.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Current Leases (2019 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 8 years of Current Leases data on file, last reported at $212769.0 in Q1 2026.
- Quarterly Current Leases fell 16.67% year-over-year to $212769.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212769.0 (down 16.67% YoY) and the FY2025 annual result came in at $280537.0, up 3.28% from the prior year.
- Current Leases retreated to $212769.0 in Q1 2026, from $280537.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $280537.0 in Q4 2025 to a low of $65628.0 in Q3 2023.
- A 5-year average of $226966.2 and a median of $247021.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases tumbled 64.45% — and 2024, when it soared 301.11%.
- Tracing ALDX's Current Leases over 5 years: stood at $249265.0 in 2022, then fell by 4.04% to $239183.0 in 2023, then gained by 13.57% to $271631.0 in 2024, then increased by 3.28% to $280537.0 in 2025, then slipped by 24.16% to $212769.0 in 2026.
- The last three Current Leases figures came in at $212769.0 (Q1 2026), $280537.0 (Q4 2025), and $271948.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Aldeyra Therapeutics | 94.10 Mn | 94.10 Mn | - | 143,447.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 143,447.00 |
| Mar 31, 2026 | 212,769.00 |
| Dec 31, 2025 | 280,537.00 |
| Sep 30, 2025 | 271,948.00 |
| Jun 30, 2025 | 263,551.00 |
| Mar 31, 2025 | 255,342.00 |
| Dec 31, 2024 | 271,631.00 |
| Sep 30, 2024 | 263,241.00 |
| Jun 30, 2024 | 255,039.00 |
| Mar 31, 2024 | 247,021.00 |
| Dec 31, 2023 | 239,183.00 |
| Sep 30, 2023 | 65,628.00 |
| Jun 30, 2023 | 129,785.00 |
| Mar 31, 2023 | 190,202.00 |
| Dec 31, 2022 | 249,265.00 |
| Sep 30, 2022 | 184,599.00 |
| Jun 30, 2022 | 242,636.00 |
| Mar 31, 2022 | 236,048.00 |
| Dec 31, 2021 | 229,607.00 |
| Sep 30, 2021 | 222,158.00 |